Published in Clin Breast Cancer on December 01, 2010
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract (2012) 1.36
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr Med Chem (2012) 1.12
Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog (2011) 0.96
HER2 therapies and gastric cancer: a step forward. World J Gastroenterol (2013) 0.96
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol (2013) 0.90
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Rev Anticancer Ther (2012) 0.90
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. J Adv Pract Oncol (2015) 0.89
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer (2014) 0.85
Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocr Relat Cancer (2013) 0.84
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother (2015) 0.81
Targeting HER2 Positive Breast Cancer with Chemopreventive Agents. Curr Pharmacol Rep (2015) 0.80
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res (2014) 0.80
Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer. Curr Breast Cancer Rep (2014) 0.79
Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity. Sci Rep (2015) 0.79
New developments in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.78
Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs (2012) 0.78
The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Oncologist (2015) 0.77
Precision medicine and personalized breast cancer: combination pertuzumab therapy. Pharmgenomics Pers Med (2014) 0.77
Next generation of antibody therapy for cancer. Chin J Cancer (2011) 0.76
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. Cancer Chemother Pharmacol (2017) 0.75
Human epidermal growth factor receptor 2-targeted therapies in breast cancer. Expert Opin Biol Ther (2013) 0.75
State of the art in anti-cancer mAbs. J Biomed Sci (2017) 0.75
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs Aging (2015) 0.75
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest (2003) 4.06
Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol (2006) 3.62
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst (2011) 3.54
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol (2006) 2.93
Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst (2004) 2.72
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol (2012) 2.34
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res (2008) 1.83
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res (2002) 1.82
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res (2008) 1.81
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol (2004) 1.72
Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther (2007) 1.68
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol (2011) 1.56
The influence of a gene expression profile on breast cancer decisions. J Surg Oncol (2009) 1.52
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res (2008) 1.50
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol (2007) 1.50
Locally advanced and inflammatory breast cancer. J Clin Oncol (2008) 1.44
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol (2005) 1.41
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Amenorrhea from breast cancer therapy--not a matter of dose. N Engl J Med (2010) 1.40
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. Radiology (2007) 1.24
ASCO's approach to a learning health care system in oncology. J Oncol Pract (2013) 1.22
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat (2010) 1.08
Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol (2011) 1.05
Therapeutic strategies for triple-negative breast cancer. Cancer J (2008) 1.05
Clinical aspects of inflammatory breast cancer. Breast Dis (2006) 1.03
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res (2013) 1.02
Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat (2011) 1.01
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol (2005) 1.00
Aromatase inhibitors--a triumph of translational oncology. N Engl J Med (2005) 1.00
Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep (2007) 0.98
Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol (2003) 0.98
Drug discount program. JAMA (2013) 0.97
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol (2010) 0.96
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res (2004) 0.95
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res (2005) 0.94
The epothilones: translating from the laboratory to the clinic. Clin Cancer Res (2008) 0.93
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res (2004) 0.92
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.92
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology (2007) 0.88
A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials. Oncologist (2012) 0.87
Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol (2006) 0.87
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs (2006) 0.86
Concepts and clinical trials of dose-dense chemotherapy for breast cancer . Clin Breast Cancer (2005) 0.86
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat (2006) 0.86
A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer (2006) 0.85
A step in the right direction. J Clin Oncol (2006) 0.85
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res (2006) 0.84
Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. Clin Breast Cancer (2012) 0.83
The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.83
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs (2007) 0.83
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer (2011) 0.83
CA 125 elevation in breast cancer: a case report and review of the literature. Breast J (2004) 0.82
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer (2014) 0.82
Primary systemic chemotherapy for inflammatory breast cancer. Cancer (2010) 0.82
Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. Cancer Med (2013) 0.82
NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med (2013) 0.81
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat (2013) 0.81
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs (2013) 0.81
Cardiac dysfunction after cancer treatment. Tex Heart Inst J (2011) 0.80
Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin Investig Drugs (2008) 0.80
The heart of the matter. J Clin Oncol (2007) 0.80
Contralateral breast cancer: where does it all begin? J Clin Oncol (2005) 0.80
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. Int J Oncol (2011) 0.79
Pertuzumab for the treatment of breast cancer. Cancer Invest (2014) 0.79
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol (2002) 0.79
Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. Expert Opin Biol Ther (2013) 0.78
Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerg Drugs (2006) 0.78
Treatment of HER2-positive metastatic breast cancer. N Engl J Med (2015) 0.77
Treatment and cost implications of pertuzumab. Am J Manag Care (2012) 0.77
A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. Clin Breast Cancer (2005) 0.76
Pazopanib for the treatment of breast cancer. Expert Opin Investig Drugs (2012) 0.76
First, do no harm. Onkologie (2008) 0.75
Meta-analysis: should it be more than the sum of its parts? J Natl Cancer Inst (2010) 0.75
Pertuzumab: increasing the options. Oncology (Williston Park) (2014) 0.75
Oophorectomy in carriers of BRCA mutations. N Engl J Med (2002) 0.75
Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer. Clin Breast Cancer (2004) 0.75
Avastin withdrawal symptoms. Expert Opin Pharmacother (2012) 0.75